Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
KZIA
KZIA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
KZIA News
Kazia's NDL2 Therapy Significantly Reduces Tumor Volume
Jan 30 2026
stocktwits
Kazia Launches First-in-Class Nuclear PD-L1 Degrader NDL2
Jan 30 2026
PRnewswire
Kazia Therapeutics Provides Clinical Update on Paxalisib in TNBC Study
Jan 27 2026
Benzinga
Kazia Therapeutics Updates on Clinical Trial Progress
Jan 27 2026
PRnewswire
Kazia CEO John Friend to Attend JPM Week, Advancing Breast Cancer Research
Jan 08 2026
Newsfilter
Oncolytics Biotech Inc. Reports 33% Response Rate for Pelareorep in Colorectal Cancer
Jan 07 2026
Newsfilter
Oncolytics Biotech's Immunotherapy Shows Significant Improvement in Cancer Treatment Outcomes
Jan 07 2026
PRnewswire
GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
Jan 05 2026
Benzinga
Kazia Regains Nasdaq Compliance Following $50 Million Institutional Financing
Dec 22 2025
PRnewswire
Kazia Regains Nasdaq Compliance Following $50 Million Institutional Financing
Dec 22 2025
Newsfilter
Market Update: Tilray Drives After-Hours Gains as Biotech Stocks Soar
Dec 15 2025
NASDAQ.COM
Kazia Reports 76% Tumor Volume Shrinkage in TNBC Trial with Paxalisib
Dec 10 2025
PRnewswire
Updates on Kazia Therapeutics: Current Developments in Cancer Research
Dec 02 2025
Benzinga
Kazia Therapeutics Secures $50 Million in PIPE Financing
Dec 02 2025
Newsfilter
What Caused Kazia Therapeutics' Over 51% Jump in After-Hours Trading?
Nov 19 2025
Benzinga
Maxim Group Reaffirms Buy Rating for Kazia Therapeutics, Increases Price Target to $20
Oct 02 2025
Benzinga
Show More News
